Health and Healthcare
Rocket Pharma Grounded Despite Positive FDA Update
Published:
Last Updated:
Rocket Pharmaceuticals Inc. (NASDAQ: RCKT) shares dipped on Tuesday after the company shared an update from the U.S. Food and Drug Administration (FDA). While the update wasn’t negative, this seems to be a case of sell the news, as the stock is up 65% in the past year.
The FDA granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to RP-L102, Rocket Pharma’s lentiviral-vector-based gene therapy for the treatment of Fanconi anemia (FA).
RMAT designation was granted based on the positive efficacy and safety results from the ongoing Phase 1/2 clinical trial of RP-L102 being conducted in Europe.
Rocket plans to initiate a clinical trial of RP-L102 for FA in early 2019 utilizing no conditioning and “Process B,” which incorporates higher cell doses, transduction enhancers and commercial-grade vector manufacturing and cell processing.
Gaurav Shah, M.D., CEO and president, commented:
The RMAT designation, which is the CBER equivalent of Breakthrough Designation with the same benefits, and Fast Track designations represent important milestones for the FA program and recognition of RP-L102 as a potential treatment for this devastating disease. Achieving these milestones further underscores the urgent need to develop new treatments for young children affected by FA that would otherwise lead to bone marrow failure and death in the absence of a hematopoietic stem cell transplantation. We look forward to working closely with the FDA on our development plan to rapidly advance RP-L102 towards potential approval.
Shares of Rocket were last seen down over 6% at $15.11, in a 52-week range of $7.84 to $25.96. The consensus analyst price target is $28.00.
24/7 Wall St.Travel Cards Are Getting Too Good To Ignore
Credit card companies are pulling out all the stops, with the issuers are offering insane travel rewards and perks.
We’re talking huge sign-up bonuses, points on every purchase, and benefits like lounge access, travel credits, and free hotel nights. For travelers, these rewards can add up to thousands of dollars in flights, upgrades, and luxury experiences every year.
It’s like getting paid to travel — and it’s available to qualified borrowers who know where to look.
We’ve rounded up some of the best travel credit cards on the market. Click here to see the list. Don’t miss these offers — they won’t be this good forever.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
